Compare IDN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDN | SGMT |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.7M | 169.4M |
| IPO Year | 2014 | 2021 |
| Metric | IDN | SGMT |
|---|---|---|
| Price | $4.33 | $6.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $7.33 | ★ $26.13 |
| AVG Volume (30 Days) | 621.4K | ★ 2.8M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,433,454.00 | $2,000,000.00 |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $15.32 | N/A |
| P/E Ratio | $140.00 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $3.67 | $3.15 |
| 52 Week High | $9.08 | $11.41 |
| Indicator | IDN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 24.47 | 45.78 |
| Support Level | N/A | $6.43 |
| Resistance Level | $5.34 | $6.84 |
| Average True Range (ATR) | 0.47 | 0.51 |
| MACD | -0.44 | -0.22 |
| Stochastic Oscillator | 7.22 | 9.84 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.